Cat. No.: HY-N0504

Copy Link Print Information

Lovastatin

(Synonyms: Mevinolin)

35 Cited Publications

Avis client

Based on 35 publication(s) in Google Scholar

Lovastatin (Mevinolin) is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.75%
CAS No.: 75330-75-5
Formule: C₂₄H₃₆O₅
Masse moléculaire:404.54

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Lovastatin Chemical Structure

CAS No.: 75330-75-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (35)
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Bioz

Activité biologique

Description

Lovastatin (Mevinolin) is a cell-permeable HMG-CoA reductase inhibitor used to lower cholesterol.

IC₅₀ & Target

HMG-CoA reductase^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	11.4 μM Compound: 1	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 23570542]
A549	IC₅₀	19.8 μM Compound: 1	Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis Inhibition of HMG-CoA reductase in human A549 cells after 5 mins by spectrophotometric analysis	[PMID: 23570542]
HEK293	IC₅₀	28 μM Compound: Lovastatin lactone	TP_TRANSPORTER: inhibition of estradiol-17beta-glucuronide uptake(estradiol-17beta-glucuronide:0.02uM) in OATP1B1-expressing HEK293 cells TP_TRANSPORTER: inhibition of estradiol-17beta-glucuronide uptake(estradiol-17beta-glucuronide:0.02uM) in OATP1B1-expressing HEK293 cells	[PMID: 15616150]
Hepatocyte	IC₅₀	32 nM Compound: Mevinolin	Compound was evaluated for inhibitory activity against HMG-CoA reductase from rat hepatocyte Compound was evaluated for inhibitory activity against HMG-CoA reductase from rat hepatocyte	10.1016/S0960-894X(00)80623-X
HepG2	IC₅₀	0.029 μM Compound: 1	Tested for inhibition of cholesterol biosynthesis in HEP G2 cells Tested for inhibition of cholesterol biosynthesis in HEP G2 cells	[PMID: 7932551]
HepG2	IC₅₀	0.079 μM Compound: 2	Tested for ability to inhibit incorporation of [14C]acetate into cholesterol in cultured human hepatoma (HEP-G2) cells; 0.061-0.10 Tested for ability to inhibit incorporation of [14C]acetate into cholesterol in cultured human hepatoma (HEP-G2) cells; 0.061-0.10	[PMID: 8246237]
HepG2	IC₅₀	37 nM Compound: mevinolin (lactone) 2	Concentration required to inhibit HMG-CoA reductase by 50% was determined in Hep G2 cell line Concentration required to inhibit HMG-CoA reductase by 50% was determined in Hep G2 cell line	[PMID: 1527791]
HepG2	IC₅₀	39 nM Compound: Mevinolin	Compound was evaluated for inhibitory activity against HMG-CoA reductase in HepG2 cells Compound was evaluated for inhibitory activity against HMG-CoA reductase in HepG2 cells	10.1016/S0960-894X(00)80623-X
HepG2	IC₅₀	50 nM Compound: 1b (Mevinolin)	Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol. Inhibition of cellular HMG-CoA reductase in cultures of human HEP G2 cells, determined by decreased incorporation of sodium [14C]acetate into cholesterol.	[PMID: 2296036]
HepG2	IC₅₀	50 nM Compound: mevinolin	Inhibition of the incorporation of sodium [14C]acetate into cholesterol in HEP G2 cells. Inhibition of the incorporation of sodium [14C]acetate into cholesterol in HEP G2 cells.	[PMID: 1656041]
HepG2	IC₅₀	8.3 μM Compound: Lovastatin	Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method Lipid lowering activity in human HepG2 cells assessed as decrease in oleic acid elicited lipid accumulation after 6 hrs by oil-red O staining method	[PMID: 26169125]
HES	IC₅₀	13 nM Compound: mevinolin (lactone) 2	Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line Concentration required to inhibit HMG-CoA reductase by 50% was determined in HES 9 cell line	[PMID: 1527791]
Hs68	IC₅₀	23.2 μM Compound: 1	Cytotoxicity against human HS68 cells after 72 hrs by MTT assay Cytotoxicity against human HS68 cells after 72 hrs by MTT assay	[PMID: 23570542]
HT-29	IC₅₀	46.8 μM Compound: Lovastatin	Growth inhibition of human HT29 cells after 96 hrs by MTS assay Growth inhibition of human HT29 cells after 96 hrs by MTS assay	[PMID: 17472962]
KB	IC₅₀	15.6 μM Compound: 2	Cytotoxicity against human KB cells by resazurin microplate assay Cytotoxicity against human KB cells by resazurin microplate assay	[PMID: 27228159]
LS180	IC₅₀	25.3 μM Compound: Lovastatin	Growth inhibition of human LS180 cells after 96 hrs by MTS assay Growth inhibition of human LS180 cells after 96 hrs by MTS assay	[PMID: 17472962]
MCF7	IC₅₀	>40 μM Compound: 1	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
MDA-MB-231	IC₅₀	>40 μM Compound: 1	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
MDCK	IC₅₀	10 μM Compound: Lovastatin lactone	TP_TRANSPORTER: inhibition of calcein-AM efflux in MDR1-expressing MDCK cells TP_TRANSPORTER: inhibition of calcein-AM efflux in MDR1-expressing MDCK cells	[PMID: 15616150]
MEF	IC₅₀	35 μM Compound: 1	Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay	[PMID: 23570542]
NIH-3T3-G185	IC₅₀	114.4 μM Compound: Lovastatin	TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of Rhodamine 123 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
NIH-3T3-G185	IC₅₀	32.7 μM Compound: Lovastatin	TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells TP_TRANSPORTER: inhibition of LDS-751 efflux in NIH-3T3-G185 cells	[PMID: 11716514]
PC-3	IC₅₀	5.4 μM Compound: 1	Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 48 hrs by SRB assay	[PMID: 27756564]
SW480	IC₅₀	7.1 μM Compound: Lovastatin	Growth inhibition of human SW480 cells after 96 hrs by MTS assay Growth inhibition of human SW480 cells after 96 hrs by MTS assay	[PMID: 17472962]
T47D	IC₅₀	>40 μM Compound: 1	Cytotoxicity against human T47D cells assessed as growth inhibition after 24 to 48 hrs by MTT assay Cytotoxicity against human T47D cells assessed as growth inhibition after 24 to 48 hrs by MTT assay	[PMID: 27756564]
THP-1	IC₅₀	8 μg/mL Compound: Lovastatin	Inhibition of sICAM1/LFA1 interaction-mediated human THP1 cell adhesion after 1 hr by ELISA Inhibition of sICAM1/LFA1 interaction-mediated human THP1 cell adhesion after 1 hr by ELISA	[PMID: 18672369]
Vero	IC₅₀	2.2 μM Compound: 2	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 27228159]

In Vitro

When Lovastatin is used in cell function experiments, it is usually necessary to convert it from the inactive "lactone ring" form to the active "open-ring hydroxy acid" form Lovastatin hydroxy acid sodium (HY-123672)^[6]^[7].
1. Dissolve 10 mg of Lovastatin in 0.2 mL of warm (55°C) anhydrous ethanol. Ultrasonic-assisted dissolution of soluble clear.
2. Add 0.1 mL of 0.6 M NaOH and 2 mL of aqueous solution and incubate at room temperature for 30 minutes.
3. Adjust the pH to 8.0 with HCl.
4. Finally, bring the volume to 2.47 mL for a final concentration of 10 mM.

Lovastatin (10 μM; 72 hours) efficiently reduces viability of HepG2 cells^[2].
Lovastatin (10 μM; 48 hours) induces apoptosis in HepG2 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

HepG2 cells
Concentration:

10 μM
Incubation Time:

72 hours
Result:

Efficiently reduced viability of HepG2 cells.

In Vivo

Lovastatin is an inactive lactone that is hydrolyzed in the liver to an active f3-hydroxyacid form. This principal metabolite is the inhibitor of the enzyme HMG-CoA reductase. The K_i is 1 nM. Lovastatin and its β-hydroxyacid metabolite are highly bound to human plasma proteins. Lovastatin crosses the blood-brain and placental barriers^[3]. Lovastatin produces a profound reduction of apolipoprotein-B-containing lipoproteins, especially LDL cholesterol and, to a lesser extent, plasma triglycerides, and a small increase in HDL cholesterol^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 75330-75-5
Appearance Solid
Masse moléculaire 404.54
Formule C₂₄H₃₆O₅
Color Off-white to light yellow
SMILES

O=C([C@@H](C)CC)O[C@@H]1[C@@]([C@H]2CC[C@@H](OC3=O)C[C@H](C3)O)([H])C(C=C[C@@H]2C)=C[C@H](C)C1
Synonyms

Mevinolin
Structure Classification
- Ketones, Aldehydes, Acids
Initial Source
- Microorganisms
aspergillus terreus
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (35)

All RT-PCRBio/Physico-chemical AssayCell Imaging/StainingIn Vivo Efficacy StudyCell Proliferation/Viability AssayWBIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]

2025 Dec 15;10(1):406. PMID: 41392286
Cell Metab

Integrating Mouse and Human Genetic Data to Move beyond GWAS and Identify Causal Genes in Cholesterol Metabolism. [Abstract]

2020 Apr 7;31(4):741-754.e5. PMID: 32197071

Lovastatin purchased from MedChemExpress. Usage Cited in: Cell Metab. 2020 Apr 7;31(4):741-754.e5. [Abstract]

Liver mRNA expression levels of 25 prioritized genes after one week of 0.02% Lovastatin (red) or control (black) treatment in male mice.
Cancer Commun (Lond)

Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. [Abstract]

2025 Aug;45(8):1010-1037. PMID: 40439109

Lovastatin purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2025 Aug;45(8):1010-1037. [Abstract]

Denifanstat (10 mg/kg; i.g.; every day; from day7 to day20); Lovastatin(10 mg/kg; i.g.; every day; from day7 to day20); Simvastatin (50 mg/kg; i.g.; every day; from day7 to day20). Tumor growth curve of each group (4 mice/group). ns, not significant; * P < 0.05, **P < 0.01, ***P < 0.001.
Nat Commun

Cholesterol-rich lysosomes induced by respiratory syncytial virus promote viral replication by blocking autophagy flux. [Abstract]

2024 Jul 26;15(1):6311. PMID: 39060258

Lovastatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 26;15(1):6311. [Abstract]

Lovastatin (25 μM; 24 h). The effect of exogenous or endogenous cholesterol on cholesterol content in infected HEp-2 cells was determined using an Amplex^TM Red Cholesterol Assay Kit and immunofluorescence assay, respectively.
Nat Commun

TRABID inhibition activates cGAS/STING-mediated anti-tumor immunity through mitosis and autophagy dysregulation. [Abstract]

2023 May 26;14(1):3050. PMID: 37237031

Lovastatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 26;14(1):3050. [Abstract]

Westernblot analysis of TRABID mRNA and protein levels in HeLa cells treated with 10 μM Lovastatin, 2 μg/ml Aphidicolin, 10 μM RO-3306, or 3 μM Nocodazole for 18 h.

Lovastatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 May 26;14(1):3050. [Abstract]

RT-qPCR analysis of TRABID mRNA and protein levels in HeLa cells treated with 10 μM Lovastatin, 2 μg/ml Aphidicolin, 10 μM RO-3306, or 3 μM Nocodazole for 18 h.
Nucleic Acids Res

Unfolding of an RNA G-quadruplex motif in the negative strand genome of porcine reproductive and respiratory syndrome virus by host and viral helicases to promote viral replication. [Abstract]

2023 Oct 27;51(19):10752-10767. PMID: 37739415
Redox Biol

Porcine reproductive and respiratory syndrome virus nsp4 positively regulates cellular cholesterol to inhibit type I interferon production. [Abstract]

2022 Feb;49:102207. PMID: 34911669
Cell Death Dis

The mevalonate coordinates energy input and cell proliferation. [Abstract]

2019 Apr 11;10(4):327. PMID: 30975976
Genome Biol

Systematic interrogation of functional genes underlying cholesterol and lipid homeostasis. [Abstract]

2025 Mar 17;26(1):59. PMID: 40098013
Int J Biol Macromol

Grass carp retinoid-related orphan receptor α (gcRORαa) promotes GCRV replication via LDLR-mediated lipid accumulation. [Abstract]

2026 Jan;339(Pt 2):150021. PMID: 41485668
EMBO Mol Med

Inhibiting cholesterol synthesis halts rhabdomyosarcoma growth via ER stress and cell cycle arrest. [Abstract]

2025 Dec;17(12):3586-3606. PMID: 41249736
Cell Biosci

Gut microbial metabolite deoxycholic acid facilitates Th17 differentiation through modulating cholesterol biosynthesis and participates in high-fat diet-associated colonic inflammation. [Abstract]

2023 Oct 3;13(1):186. PMID: 37789469
Ecotoxicol Environ Saf

Interleukin-24: A molecular mediator of particulate matter's impact on skin aging. [Abstract]

2024 Jul 18:282:116738. PMID: 39029221
JCI Insight

Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer. [Abstract]

2022 Sep 22;7(18):e161940. PMID: 35943796
Chin Med

Daidzein improves muscle atrophy caused by lovastatin by regulating the AMPK/FOXO3a axis. [Abstract]

2024 Dec 31;19(1):180. PMID: 39741316
Clin Pharmacol Ther

Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™). [Abstract]

2025 Jul 14. PMID: 40657937
Pharmaceutics

Drug-Induced Reorganisation of Lipid Metabolism Limits the Therapeutic Efficacy of Ponatinib in Glioma Stem Cells. [Abstract]

2024 May 29;16(6):728. PMID: 38931850
Front Bioeng Biotechnol

Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation. [Abstract]

2022 Mar 17;10:826093. PMID: 35372314
Toxicology

Statin induces epithelial cell death and tissue barrier damage in renal tubule on chip. [Abstract]

2025 Oct 13:519:154309. PMID: 41093097

Lovastatin purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Oct 13:519:154309. [Abstract]

Renal tubular epithelial cells were treated with DMSO, 3 mM Pyruvic acid sodium, and 25 μM lovastatin (with or without 3 mM Pyruvic acid sodium) for 48 hours. ROS generation of the microarray epithelial cells was assessed by DCFH-DA staining.

Lovastatin purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Oct 13:519:154309. [Abstract]

Renal tubular epithelial cells were treated with DMSO, 3 mM Pyruvic acid sodium, and 25 μM lovastatin (with or without 3 mM Pyruvic acid sodium) for 48 hours. Damage to renal tubular epithelial cells on the chip was measured using the LDH assay.
Front Cell Dev Biol

Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. [Abstract]

2022 Mar 3;10:806081. PMID: 35309902
ACS Omega

Computational Approaches to Identify Molecules Binding to Mycobacterium tuberculosis KasA. [Abstract]

2020 Nov 15;5(46):29935-29942. PMID: 33251429
Front Cell Dev Biol

Construction of Escherichia coli Whole-Cell Biosensors for Statin Efficacy and Production Test. [Abstract]

2020 May 28;8:404. PMID: 32671060
J Gen Virol

Engagement of cellular cholesterol in the life cycle of classical swine fever virus: its potential as an antiviral target. [Abstract]

2019 Feb;100(2):156-165. PMID: 30484759
Environ Toxicol Pharmacol

Assessment of the toxicity of acrolein on an alveolus microphysiological system. [Abstract]

2026 Mar:122:104954. PMID: 41644025
iScience

Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer. [Abstract]

2025 Jan 21;28(2):111864. PMID: 39995872
Antiviral Res

Targeting 7-dehydrocholesterol reductase against EV-A71 replication by upregulating interferon response. [Abstract]

2023 Jan:209:105497. PMID: 36528172

Lovastatin purchased from MedChemExpress. Usage Cited in: Antiviral Res. 2023 Jan:209:105497. [Abstract]

Pretreatment with AY9944 (15, 30 µM), U18666A (5, 10 µM), Lovastatin (5, 10 µM) and MβCD for 2 h can all significantly reduce the level of EV-A71 VP1 protein in HCT-8 cell.
J Hepatocell Carcinoma

miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway. [Abstract]

2023 Dec 6:10:2173-2185. PMID: 38084209
Cell Cycle

Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. [Abstract]

2019 Dec;18(23):3337-3350. PMID: 31599189
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
FEBS Open Bio

Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis. [Abstract]

2025 Aug 8. PMID: 40781787
Biochem Biophys Res Commun

Lovastatin attenuates angiotensin II induced cardiovascular fibrosis through the suppression of YAP/TAZ signaling. [Abstract]

2019 May 14;512(4):736-741. PMID: 30926167
bioRxiv

2026 Feb 3.
bioRxiv

2025 Sep 4.
University of New Hampshire

2021 Oct.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (247.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 50 mg/mL (123.60 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4719 mL

12.3597 mL

24.7194 mL

5 mM

0.4944 mL

2.4719 mL

4.9439 mL

10 mM

0.2472 mL

1.2360 mL

2.4719 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (283 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Alberts AW, et al. Discovery, biochemistry and biology of lovastatin. Am J Cardiol. 1988 Nov 11;62(15):10J-15J. [Content Brief]

[2]. Kah J, et al. Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression. Oncol Rep. 2012 Sep;28(3):1077-83. [Content Brief]

[3]. Frishman WH, et al. Lovastatin: an HMG-CoA reductase inhibitor for lowering cholesterol. Med Clin North Am. 1989 Mar;73(2):437-48. [Content Brief]

[4]. Tobert JA, et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003 Jul;2(7):517-26. [Content Brief]

[5]. Ifergan I, et al. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006 Jul;60(1):45-55. [Content Brief]

[6]. Chu W, et al. Lovastatin exerts protective effects on endothelial cells via upregulation of PTK2B. Exp Ther Med. 2016 Sep;12(3):1741-1749. [Content Brief]

[7]. Régrigny O, et al. Effect of lovastatin on cerebral circulation in spontaneously hypertensive rats. Hypertension. 2000 May;35(5):1105-10. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.4719 mL	12.3597 mL	24.7194 mL	61.7986 mL
	5 mM	0.4944 mL	2.4719 mL	4.9439 mL	12.3597 mL
	10 mM	0.2472 mL	1.2360 mL	2.4719 mL	6.1799 mL
	15 mM	0.1648 mL	0.8240 mL	1.6480 mL	4.1199 mL
	20 mM	0.1236 mL	0.6180 mL	1.2360 mL	3.0899 mL
	25 mM	0.0989 mL	0.4944 mL	0.9888 mL	2.4719 mL
	30 mM	0.0824 mL	0.4120 mL	0.8240 mL	2.0600 mL
	40 mM	0.0618 mL	0.3090 mL	0.6180 mL	1.5450 mL
	50 mM	0.0494 mL	0.2472 mL	0.4944 mL	1.2360 mL
	60 mM	0.0412 mL	0.2060 mL	0.4120 mL	1.0300 mL
	80 mM	0.0309 mL	0.1545 mL	0.3090 mL	0.7725 mL
	100 mM	0.0247 mL	0.1236 mL	0.2472 mL	0.6180 mL

Keywords

Lovastatin

35 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Lovastatin

Anti-Infection Compound Library

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Cancer Metabolism Compound Library

Microbial Metabolite Library

Lipid Metabolism Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Fungal-Sourced Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Lovastatin

Activité biologique

Chemical Information

Publications (35)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Lovastatin Related Classifications

Cat. No.: HY-N0504